Iodide

Iodide

SCHEMBL964573

COc1cc(N=C(N)SC)ccc1-c1cnn(C)c1.I

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 1/20 0.45
PLAU P00749 1/20 0.41
USP30 Q70CQ3 4/20 0.40
FYN P06241 1/20 0.40
ERN1 O75460 1/20 0.40
HTR3E A5X5Y0 1/20 0.39
HTR3B O95264 1/20 0.39
HTR3A P46098 1/20 0.39
HTR3D Q70Z44 1/20 0.39
HTR3C Q8WXA8 1/20 0.39
NOS3 P29474 3/20 0.38
NOS1 P29475 3/20 0.38
NOS2 P35228 2/20 0.38
PSEN1 P49768 1/20 0.37
PSEN2 P49810 1/20 0.37
APH1B Q8WW43 1/20 0.37
NCSTN Q92542 1/20 0.37
APH1A Q96BI3 1/20 0.37
PSENEN Q9NZ42 1/20 0.37
LRRK2 Q5S007 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12918153 0.99 AAK1 (0.46) AAK1PLAUUSP30FYNERN1
Iodide SCHEMBL964663 0.77 HTR3E (0.39) AAK1HTR3EHTR3BHTR3AHTR3D
SCHEMBL12918156 0.76 HTR3E (0.40) AAK1HTR3EHTR3BHTR3AHTR3D
SCHEMBL963976 0.75 AAK1 (0.44) AAK1PLAUUSP30FYNERN1
SCHEMBL29877325 0.73 AAK1 (0.52) AAK1PLAUUSP30ERN1PSEN1
SCHEMBL512461 0.73 AAK1 (0.52) AAK1PLAUUSP30ERN1PSEN1
SCHEMBL19998607 0.72 AAK1 (0.50) AAK1PLAUUSP30FYNERN1
Iodide SCHEMBL2539386 0.72 HTR3E (0.38) HTR3EHTR3BHTR3AHTR3DHTR3C
Iodide SCHEMBL964547 0.71 IMPDH2 (0.43) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL961096 0.71 AAK1 (0.64) AAK1PLAUUSP30PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379553-B1 BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2013-06-26 EP disclosed
US-8349880-B2 Bicyclic compounds for the reduction of beta-amyloid production BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-08 US disclosed
EP-2379553-A1 BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION Bristol-Myers Squibb Company (US) 2011-10-26 EP disclosed
US-20110015175-A1 Bicyclic Compounds for the Reduction of Beta-Amyloid Production BRISTOL-MYERS SQUIBB COMPANY 2011-01-20 US disclosed
WO-2010083141-A1 BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015175-A1 Bicyclic Compounds for the Reduction of Beta-Amyloid Production APP, BACE1, APBA1 AAK1 837/4885PLAU 2579/4885USP30 3929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.